Literature DB >> 16184554

Homozygous deletion of p16INK4a and tobacco carcinogen exposure in nonsmall cell lung cancer.

Kim S Kraunz1, Heather H Nelson, Miriam Lemos, John J Godleski, John K Wiencke, Karl T Kelsey.   

Abstract

Inactivation of p16(INK4a) in the Rb pathway is among the most common somatic alterations observed in nonsmall cell lung cancers (NSCLCs). While epigenetic inactivation of the p16(INK4a) gene promoter has been shown to be associated with increased tobacco carcinogen exposure, little investigation of any similar association of homozygous deletion or mutation of p16(INK4a) and tobacco use has been completed. In 177 consecutive NSCLCs, we examined the determinants of p16(INK4a) homozygous deletion and mutation, including the pattern of tobacco smoking and asbestos exposure. We observed that p16(INK4a) homozygous deletion occurred at a higher frequency in never smokers as compared to former and current smokers (p = 0.01). This observation suggested that tumors from these patients might be more prone to DNA deletion events; consistent with this, epigenetic silencing of the DNA double-strand break repair genes FancF and BRCA1 was also associated with homozygous deletion of p16(INK4a)(p = 0.002 and p = 0.06, respectively). Finally, mutation of p16(INK4a) was rare and only occurred in patients who were smokers. Hence, the character of somatic alteration in the Rb pathway (deletion, mutation or methylation silencing) in NSCLC is associated with the pattern of tobacco exposure, suggesting that susceptibility to lung cancer is, at least in part, mediated by the biological mechanism that selects for the character of the induced somatic lesion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16184554     DOI: 10.1002/ijc.21522

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

Review 1.  Epigenetic mechanisms in anti-cancer actions of bioactive food components--the implications in cancer prevention.

Authors:  B Stefanska; H Karlic; F Varga; K Fabianowska-Majewska; Ag Haslberger
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 2.  Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation.

Authors:  C-Q Zhu; W Shih; C-H Ling; M-S Tsao
Journal:  J Clin Pathol       Date:  2006-08       Impact factor: 3.411

3.  Role of p16 deletion and BAP1 loss in the diagnosis of malignant mesothelioma.

Authors:  Jing Liu; Xuanzhi Liao; Yingying Gu; Lin Fu; Jin Zhao; Longguang Li; Zhucheng Chen; Juhong Jiang
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  CDKN2A/p16 inactivation mechanisms and their relationship to smoke exposure and molecular features in non-small-cell lung cancer.

Authors:  Kit W Tam; Wei Zhang; Junichi Soh; Victor Stastny; Min Chen; Han Sun; Kelsie Thu; Jonathan J Rios; Chenchen Yang; Crystal N Marconett; Suhaida A Selamat; Ite A Laird-Offringa; Ayumu Taguchi; Samir Hanash; David Shames; Xiaotu Ma; Michael Q Zhang; Wan L Lam; Adi Gazdar
Journal:  J Thorac Oncol       Date:  2013-11       Impact factor: 15.609

Review 5.  Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos.

Authors:  Brooke T Mossman; Morton Lippmann; Thomas W Hesterberg; Karl T Kelsey; Aaron Barchowsky; James C Bonner
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

6.  The transcriptional consequences of somatic amplifications, deletions, and rearrangements in a human lung squamous cell carcinoma.

Authors:  Lucy F Stead; Stefano Berri; Henry M Wood; Philip Egan; Caroline Conway; Catherine Daly; Kostas Papagiannopoulos; Pamela Rabbitts
Journal:  Neoplasia       Date:  2012-11       Impact factor: 5.715

7.  Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients.

Authors:  Penny Nymark; Mervi Aavikko; Jussi Mäkilä; Salla Ruosaari; Tuija Hienonen-Kempas; Harriet Wikman; Kaisa Salmenkivi; Risto Pirinen; Antti Karjalainen; Esa Vanhala; Eeva Kuosma; Sisko Anttila; Eeva Kettunen
Journal:  Mol Oncol       Date:  2012-08-07       Impact factor: 6.603

8.  Genetic and epigenetic tumor suppressor gene silencing are distinct molecular phenotypes driven by growth promoting mutations in nonsmall cell lung cancer.

Authors:  Carmen J Marsit; E Andres Houseman; Heather H Nelson; Karl T Kelsey
Journal:  J Cancer Epidemiol       Date:  2009-01-28

9.  Quality assessment of DNA derived from up to 30 years old formalin fixed paraffin embedded (FFPE) tissue for PCR-based methylation analysis using SMART-MSP and MS-HRM.

Authors:  Lasse S Kristensen; Tomasz K Wojdacz; Britta B Thestrup; Carsten Wiuf; Henrik Hager; Lise Lotte Hansen
Journal:  BMC Cancer       Date:  2009-12-21       Impact factor: 4.430

10.  Survivin expression in normal human bronchial epithelial cells: an early and critical step in tumorigenesis induced by tobacco exposure.

Authors:  Quanri Jin; David G Menter; Li Mao; Waun Ki Hong; Ho-Young Lee
Journal:  Carcinogenesis       Date:  2008-07-16       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.